本报（chinatimes.net.cn）记者张玫 北京报道 A股市场延续结构性行情，百亿私募机构的调仓动向成为市场关注焦点。 私募排排网数据显示，根据最新披露的持仓数据，高毅资产、迎水投资、通怡投资等多家头部私募在 2025年第二季度进行了显著调仓，其中化工、食品饮料等板块被持续看好，龙佰集团、安琪酵母等个股 获得明显增持。 高毅持仓总市值位居前列 作为私募行业的领头羊，高毅资产二季度持仓总市值仍居前列，但其对重仓股进行了明显调整。海康威 视仍为其第一重仓股，持股市值高达93.73亿元，但或许出于获利了结等原因，本期减持约13.72亿元。 此外，高毅还减持了国瓷材料、东诚药业等电子和医药个股。 | | | | 2025年二季度百亿私募重仓股数据统计 | | | | --- | --- | --- | --- | --- | --- | | 私募简称 | 股票简称 | 持股市值(万元) | 本期持股变动(万元) | | 持股数量(万股)本期持股变动(万股) | | | 海康威视 | 937274 | -137226 | 33800 | -1200 | | | 龙佰集团 | 142648 | 248 | 880 ...

国海证券研报指出，安琪酵母2025H1实现归母净利润8.0亿元，同比+15.7%；其中2025Q2实现归母净利 润4.3亿元，同比+15.4%。2025H1公司酵母系列产品收入同比增长12.4%，高于整体营收增速。2025Q2 分品类来看，公司酵母及深加工/制糖/包装/其他业务分别实现营收29.8/2.3/1.0/7.8亿元，同比分别 +11.7%/+20.1%/+3.6%/+9.3%。2025Q2分地区来看，国内/国外实现营收23.1/17.8亿元，同比 +4.3%/+22.3%，国内市场稳健增长，海外业务实现全面增长。公司持续加强海外子公司建设，推进营 销人员本土化，新兴市场客户开发成效显著。现金流改善明显，2025H1公司实现经营性净现金流2.62亿 元，同比大幅增长。由于公司上半年扣非利润快速增长，该行上调盈利预测，维持"买入"评级。 ...

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company has shown significant growth in overseas revenue, with a notable increase in profit margins due to cost improvements [5] - The company achieved a revenue of 7.9 billion yuan in H1 2025, representing a year-on-year increase of 10.1%, and a net profit of 800 million yuan, up 15.7% year-on-year [4][5] - The company is expected to continue its growth trajectory with projected revenues of 16.68 billion yuan, 18.28 billion yuan, and 19.97 billion yuan for 2025, 2026, and 2027 respectively, with corresponding net profits of 1.596 billion yuan, 1.826 billion yuan, and 2.074 billion yuan [5][7] Summary by Sections Financial Performance - In Q2 2025, the company reported a revenue of 4.11 billion yuan, a year-on-year increase of 11.2%, and a net profit of 430 million yuan, up 15.4% year-on-year [4] - The company's gross margin reached 26.1% in H1 2025, an increase of 1.8 percentage points year-on-year, primarily due to cost improvements [5] - The operating cash flow for H1 2025 was 262 million yuan, showing a significant increase compared to the previous year [5] Revenue Breakdown - The company's yeast product revenue grew by 12.4% year-on-year, outpacing overall revenue growth [5] - In Q2 2025, revenue from domestic and international markets was 2.31 billion yuan and 1.78 billion yuan respectively, with year-on-year growth of 4.3% and 22.3% [5] Profitability Forecast - The company is projected to achieve an EPS of 1.84 yuan, 2.10 yuan, and 2.39 yuan for 2025, 2026, and 2027 respectively, with corresponding P/E ratios of 21, 18, and 16 [5][7]

Core Viewpoint - Angel Yeast (600298.SH) is advancing its biotechnology research and industrialization process with a new investment of approximately 502 million yuan in a biomanufacturing center project, reinforcing its strategic goal of becoming a leading global yeast and biotechnology company [1][2]. Group 1: Investment and Projects - The biomanufacturing center project is estimated to cost 502 million yuan, funded by the company's own resources, and is planned to be located next to the company's headquarters, covering an area of about 23 acres, with completion expected in the second half of 2027 [1]. - In addition to the biomanufacturing center, Angel Yeast announced a 230 million yuan investment in a serum-free cell culture medium core technology project, aimed at enhancing product innovation and market transition [2]. Group 2: Market Position and Financial Performance - Angel Yeast is the second-largest yeast company globally, with a total yeast production capacity exceeding 450,000 tons, holding a 55% market share in China and over 20% globally [1]. - The company has maintained stable revenue growth since surpassing 10 billion yuan in revenue in 2021, with projected revenue of 15.197 billion yuan for 2024. In Q1 2025, the company reported total revenue of 3.794 billion yuan, reflecting an 8.95% year-on-year increase, and a net profit of 370 million yuan, up 16.02% year-on-year [2].